CVS Group plc (LSE:CVSG) shares rose 1.31% to 1,316.0p in the latest market screen, gaining 17.00p and taking the veterinary services group's market capitalisation to around £870 million.

The shares have been recovering since falling around 6% on the publication of full-year results in late September, supported by the conclusion of the Competition and Markets Authority (CMA) investigation into the veterinary sector.

Key Highlights

For the year ended 30 June 2026, CVS reported revenue of £712.8 million, up 5.9%, and adjusted EBITDA of £141.5 million, up 5.1%. Adjusted EPS rose 6.9% to 85.6p.

Like-for-like sales growth was 2.1%, improved from 0.2% the prior year, although second-half growth slowed due to extreme hot weather in the UK.

The CMA published its final remedies order on 22 September 2026, ending a five-year regulatory process.

The company declared a final dividend of 9.0p, up 5.9%, and continues a £50 million share buyback. Trading in the new financial year started positively, with performance expected in line with FY27 market expectations.

About CVS Group plc

CVS Group plc (LSE:CVSG) is a UK-listed veterinary services group, operating veterinary practices in the UK and Australia, alongside laboratories and an online retail business.

Veterinary practices generate around 89% of group revenue, with laboratories contributing around 4.5% and online retail around 7%.

CVS has been expanding in Australia, acquiring practices such as Animal Medical Centre Veterinary Hospital and Helensburgh Veterinary Clinic, and expects to resume UK acquisitions following the CMA's conclusion.

Why Is LSE:CVSG Up Today?

The 1.31% rise to 1,316.0p reflects continued recovery after the results-day sell-off. Investors appear to be responding to the regulatory clarity provided by the CMA's final order, which removes a major source of uncertainty.

The ongoing share buyback provides support, and the company's positive start to the new financial year adds confidence.

UK mid-cap stocks have also seen improved sentiment on some days, supporting the move.

Key Reasons Behind the Uptick

One key factor is CMA certainty. The conclusion of the investigation allows CVS to focus on growth and resume UK acquisitions.

A second factor is Australian expansion, which provides growth outside the UK.

Third, the £50 million buyback supports EPS growth and the share price.

Fourth, improved like-for-like growth of 2.1% shows recovery from the weak prior year.

Key Growth Catalysts

The most important catalyst for LSE:CVSG is UK acquisition activity, which is resuming following the CMA's conclusion.

Australian growth through acquisitions could expand the group's scale.

Healthy Pet Club Advanced and digital initiatives could drive customer loyalty and revenue.

CEO succession will be an important milestone, with Richard Fairman planning to retire once a successor is appointed.

Like-for-like recovery in the UK would boost earnings.

Risks

The main risk for LSE:CVSG is the impact of CMA remedies, including pricing transparency and prescription fee measures, which could compress margins.

Weak UK consumer confidence could reduce demand for routine preventative care.

Leverage has risen, with net bank borrowings of £199.6 million, though leverage remains around 1.6x EBITDA.

Statutory profit is much lower than adjusted profit due to amortisation, acquisition costs and other items.

CEO succession uncertainty.

Valuation

At 1,316.0p, CVS has a market capitalisation of around £870 million. Based on adjusted EPS of 85.6p, the shares trade on roughly 15 times earnings.

The shares remain below their 52-week high of around 1,648p.

The key valuation question is whether CVS can deliver accelerating growth now that regulatory uncertainty has been removed.

Capital Returns

CVS declared a final dividend of 9.0p, up 5.9%, and has raised its dividend for several consecutive years.

The company is executing a £50 million share buyback, having repurchased shares at an average price of around £12.75.

What Investors Should Watch Next

Investors in LSE:CVSG will watch for UK and Australian acquisitions, the appointment of a new CEO and early FY27 trading.

The financial impact of CMA remedies will also be closely monitored.

Overall, the 1.31% rise in LSE:CVSG to 1,316.0p reflects continued recovery supported by regulatory clarity, buybacks and Australian expansion. At the same time, CMA remedies, consumer weakness and leverage remain key risks.